MedTrace Logo

Phase I Study of Topical CRx-191 in Normal Healthy Volunteers

NCT00544687 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2007-11-15

No results posted yet for this study

Summary

CRx-191 is a proprietary synergistic combination drug candidate being evaluated by CombinatoRx for topical psoriasis therapy. CRx-191 was identified via a proprietary screening assay for novel drug combinations demonstrating enhanced inhibition of tumor necrosis factor- alpha and interferon-gamma release, cytokines that are implicated in the pathogenesis of psoriasis.

Conditions

  • Healthy

Interventions

DRUG

CRx-191

topical (mometasone furoate + nortriptyline HCl)

DRUG

mometasone furoate

topical mometasone furoate

DRUG

nortriptyline HCl

topical nortriptyline HCl

DRUG

Karison® Creme

topical Karison® Creme (clobetasol-17-propinate 0.05%)

DRUG

Vehicle

topical (placebo)

Sponsors & Collaborators

  • Zalicus

    lead INDUSTRY

Principal Investigators

  • Johannes Gassmueller, M.D. · Bioskin GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Completion
2007-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00544687 on ClinicalTrials.gov